Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.
Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.
复制标题
开发和验证白细胞介素 6 列线图以预测克罗恩病患者对英夫利昔单抗的原发性无反应
DOI：
10.3389/fphar.2021.654985
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Shen J
中科院分区：
文献类型：
--
作者：
Chen Y;Li H;Feng Q;Shen J
背景：英夫利西单抗（IFX）治疗克罗恩病（CD）的原发性无应答（PNR）率为20%至46%。检测到PNR减少了特定治疗的不当使用。迄今为止，几乎没有任何关于PNR早期标志物的知识。本研究的目的是评估白细胞介素-6（IL-6）作为IFX治疗CD的PNR的早期预测因子的作用。 方法：我们纳入了2016年1月至2020年5月诊断为CD的322例生物初治患者。在第14周确定主要缓解。多变量logistic回归用于构建预测模型。在验证队列中评估曲线下面积（AUC）、校准和决策曲线分析（DCA）。分析GEO数据以确定IL-6在IFX治疗CD中的潜在机制。 结果：31.06%（100/322）的患者在第14周时发生PNR。IFX治疗后IL-6水平显著降低（p < 0.001）。含有IL-6的验证模型呈现出增强的区分度，AUC为0.908，校准度高。决策曲线分析（DCA）表明，该模型增加了额外的预测价值。GEO数据证实PNR组IL-6水平升高，IL-6相关差异表达基因（DEG）在炎症反应中富集。 结论：我们得出结论，IL-6可以作为一个预测因素，以评估PNR的风险，IFX治疗。
Background: The primary non-response (PNR) rate of infliximab (IFX) varies from 20 to 46% for the treatment of Crohn’s disease (CD). Detected PNR reduces the improper use of specific treatments. To date, there is hardly any knowledge regarding early markers of PNR. The aim of this study was to evaluate the role of Interleukin-6 (IL-6) as an early predictor of PNR of IFX for the treatment of CD. Methods: We enrolled 322 bio-naïve patients diagnosed with CD from January 2016 to May 2020. Primary response was determined at week 14. Multivariable logistic regression was used to construct prediction models. Area under the curve (AUC), calibration and decision curve analyses (DCA) were assessed in the validation cohort. GEO data were analyzed to identify potential mechanisms of IL-6 in IFX therapy for CD. Results: PNR occurred in 31.06% (100 of 322) patients who were assessable at week 14. IL-6 levels significantly decreased after IFX therapy (p < 0.001). The validation model containing IL-6 presented enhanced discrimination with an AUC of 0.908 and high calibration. Decision curve analysis (DCA) indicated that the model added extra predictive value. GEO data confirmed the IL-6 levels were increased in the PNR group and IL-6-related differentially expressed genes (DEGs) were enriched in the inflammatory response. Conclusions: We concluded that IL-6 may be used as a predictive factor to assess the risk of PNR to IFX therapy.
登录
查看更多内容
影响因子：
14.9
作者：
Ritchie ME;Phipson B;Wu D;Hu Y;Law CW;Shi W;Smyth GK
通讯作者：
Smyth GK
starBase v2.0：从大规模 CLIP-Seq 数据中解码 miRNA-ceRNA、miRNA-ncRNA 和蛋白质-RNA 相互作用网络
影响因子：
14.9
作者：
Li JH;Liu S;Zhou H;Qu LH;Yang JH
通讯作者：
Yang JH
影响因子：
4.9
作者：
Chen ML;Sundrud MS
通讯作者：
Sundrud MS
影响因子：
29.4
作者：
Ng, Siew C.;Tang, Whitney;Chan, Francis K. L.
通讯作者：
Chan, Francis K. L.
DOI：
10.1038/mt.2015.214
发表时间：
2016-04
期刊：
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子：
--
作者：
Petta I;Lievens S;Libert C;Tavernier J;De Bosscher K
通讯作者：
De Bosscher K